Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc (INBS) delivers innovative diagnostic solutions through its biosensor platform and fingerprint-based drug screening systems. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in non-invasive testing technologies.
Access comprehensive coverage of earnings reports, regulatory milestones, and product development progress. Stay informed about strategic partnerships and clinical validation studies that shape INBS’s position in life sciences. Our curated news collection simplifies tracking critical developments in portable drug screening and chronic disease monitoring solutions.
Discover updates on the Intelligent Fingerprinting Products segment’s commercial deployments and the evolving Biosensor Platform Technology applications. Bookmark this page for efficient monitoring of INBS’s contributions to modern healthcare diagnostics and workplace safety innovations.
Intelligent Bio Solutions (Nasdaq: INBS) showcased its Intelligent Fingerprinting Drug Screening Solution at the UK's premier Health & Safety Event 2024. The event, featuring over 250 exhibitors and 11,500 attendees from major brands like Amazon and Rolls Royce, provided a platform for INBS to demonstrate its innovative technology. Key decision-makers, who constituted 77% of attendees, engaged with the solution, noting its pivotal role in enhancing workplace safety. Live demonstrations with clients like Stewart Osmond from WTW highlighted the technology's effectiveness in combating drug driving in the logistics sector. Discussions with a South American distributor suggested potential expansion into Chilean hospitals and emergency services. The event was marked as the most successful yet by INBS, validating the necessity and global relevance of their drug screening technology.
Intelligent Bio Solutions Inc. (INBS) reported an 80% increase in revenue for the fiscal third quarter and a 193% increase for the nine months ended March 31, 2024. Cash and cash equivalents stood at $9.40 million. The company started FDA 510(k) clinical studies with Cliantha Research and aims for US entry in 2025. INBS secured 26 new customer accounts, totaling around 16,779 employees. The total revenue for the fiscal third quarter was $0.82 million, a 80% hike from the previous year. A net loss of $2.98 million was reported, including non-cash expenses. The Company raised approximately $10.76 million in the fiscal quarter. Financial highlights include growth in revenue from sales of goods and a decrease in net loss attributable to INBS. Operational highlights consist of significant partnerships and a new European patent for its technology.
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
